Candel Therapeutics (CADL) Share-based Compensation (2020 - 2025)
Candel Therapeutics (CADL) posted Share-based Compensation of $1.3 million for Q4 2025, up 10.92% sequentially from $1.2 million in Q3 2025, and up 3.7% YoY from $1.2 million in Q4 2024.
Candel Therapeutics (CADL) Share-based Compensation (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Share-based Compensation for 6 years, with the latest figure at $1.3 million in Q4 2025.
- Quarterly Share-based Compensation rose 3.7% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (down 28.14% YoY) and the FY2025 annual result came in at $3.8 million, down 28.14% from the prior year.
- Share-based Compensation grew to $1.3 million in Q4 2025 per CADL's latest filing, from $1.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.9 million in Q3 2021 and troughed at -$446000.0 in Q4 2021.
- A 5-year average of $874500.0 and a median of $841000.0 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 2200.0% in 2021, down 125.44% in 2021.
- Over 5 years, Share-based Compensation stood at -$446000.0 in 2021, then soared by 242.15% to $634000.0 in 2022, then soared by 48.11% to $939000.0 in 2023, then surged by 32.48% to $1.2 million in 2024, then increased by 3.7% to $1.3 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.3 million, $1.2 million, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.29 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 314,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 1.24 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 939,000.00 |
| Dec 31, 2023 | 939,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Sep 30, 2023 | 686,000.00 |